US 12,454,578 B2
Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors
Martin Pulé, London (GB); Shaun Cordoba, London (GB); Simon Thomas, London (GB); Shimobi Onuoha, London (GB); Mathieu Ferrari, London (GB); Wen Chean Lim, London (GB); and Biao Ma, London (GB)
Assigned to AUTOLUS LIMITED, London (GB)
Filed by AUTOLUS LIMITED, London (GB)
Filed on May 17, 2022, as Appl. No. 17/746,642.
Application 17/746,642 is a continuation of application No. 17/279,874, granted, now 12,049,510, previously published as PCT/GB2019/052726, filed on Sep. 26, 2019.
Claims priority of application No. 1815775 (GB), filed on Sep. 27, 2018; and application No. 1902021 (GB), filed on Feb. 14, 2019.
Prior Publication US 2022/0356260 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2878 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 2239/28 (2023.05); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2319/03 (2013.01)] 4 Claims
 
1. A cytolytic immune cell which expresses:
a) a first chimeric antigen receptor (CAR) which binds B cell maturation antigen (BCMA), wherein the BCMA CAR comprises a Fab antigen binding domain comprising the VH domain of SEQ ID NO: 29 and the VL domain of SEQ ID NO: 30; and
b) a second CAR which binds CD19, wherein the CD19 CAR comprises an scFv comprising the VH domain of SEQ ID NO: 67 and the VL domain of SEQ ID NO: 75.